$AMGN Recent Headlines Cal-Maine Foods shares fall on

New Post Public Reply Private Reply Replies (0) Message Board

Dec 26, 2014 at 12:16 PM

$AMGN Recent Headlines

Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
Amgen boosts first-quarter dividend 30% to 79 cents a share 5:46 p.m. Dec. 17, 2014 - Tom Bemis
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com

Stock Market News for December 26, 2014 - Market News 10:10 a.m. Today - Zacks.com
After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst Blog 9:25 a.m. Today - Zacks.com
4 Biotech Stocks that Doubled in 2014 - Analyst Blog 9:00 a.m. Today - Zacks.com
I'm Waiting Till The Carnage In Biotech Stocks Subsides To Buy Amgen 7:53 a.m. Today - Seeking Alpha
Cytokinetics Rises After Extending Astellas Agreement - Analyst Blog 5:10 p.m. Dec. 24, 2014 - Zacks.com
Endo/BioDelivery File Regulatory Application for Pain Drug - Analyst Blog 4:45 p.m. Dec. 24, 2014 - Zacks.com
Biotech Stocks Take A Beating, But Find Support 3:56 p.m. Dec. 24, 2014 - Investors Business Daily
Biggest Movers in Healthcare Stocks Now – TARO LPNT THC GILD 1:30 p.m. Dec. 24, 2014 - InvestorPlace.com
Are There Any Winners Left In The Biotech Space? 12:01 p.m. Dec. 24, 2014 - benzinga.com
Stock Market News for December 24, 2014 - Market News 10:10 a.m. Dec. 24, 2014 - Zacks.com
Why I Expect The Biotech Sell-Off To Continue Into 2015 8:08 a.m. Dec. 24, 2014 - Seeking Alpha
Achillion Gains on Positive Results from its HCV Candidates - Analyst Blog 5:00 p.m. Dec. 23, 2014 - Zacks.com
Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog 4:30 p.m. Dec. 23, 2014 - Zacks.com
Amgen - Not Worth Buying At Its Elevated Valuation 10:10 a.m. Dec. 23, 2014 - Seeking Alpha
Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog 6:10 p.m. Dec. 22, 2014 - Zacks.com
AstraZeneca's Lynparza Cleared in U.S. for Ovarian Cancer - Analyst Blog 5:45 p.m. Dec. 22, 2014 - Zacks.com
AbbVie's All-Oral, Interferon-Free HCV Treatment Approved - Analyst Blog 5:24 p.m. Dec. 22, 2014 - Zacks.com
Express Scripts Picks AbbVie HCV Drugs Over Gilead 4:59 p.m. Dec. 22, 2014 - Investors Business Daily
Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog 3:20 p.m. Dec. 22, 2014 - Zacks.com
Dow Stars, Biotech Lead 13 Dividend Stocks Increasing Payouts 5:13 a.m. Dec. 22, 2014 - InvestorPlace.com

Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts 9:15 a.m. Dec. 22, 2014 - PR Newswire - PRF
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience 7:00 a.m. Dec. 22, 2014 - GlobeNewswire
Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend 5:45 p.m. Dec. 17, 2014 - PR Newswire - PRF
Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 10:23 a.m. Dec. 17, 2014 - PR Newswire - PRF
TetraLogic Provides Update on Ovarian Cancer Study 7:01 a.m. Dec. 16, 2014 - GlobeNewswire
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 9:00 a.m. Dec. 8, 2014 - PR Newswire - PRF
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors 8:01 a.m. Dec. 8, 2014 - GlobeNewswire
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ECRI Welcomes Safety Expert Meshkati to Its Board

The Safety Maverick Steps into Healthcare They've gone and done it—appointed a rockstar of systems safety to ECRI's Board of Trustees. Professor Najmedin Meshkati, who's practically been around every major industrial accident of the past few decades, is about to shake things up. Imagine the guy who's dissected calamities like the BP Texas City Refinery explosion and the...

Argo Biopharma's BW-20805 Shows Promise in HAE Phase II Trial

Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...

Regeneron: Investors Face Class Action Over Study Flaws

Regeneron Investors Grit Teeth Amid Lawsuit Drama The gloves are off in the pharmaceutical battleground, folks. Investors who thought they were riding the big wave with Regeneron Pharmaceuticals (NASDAQ: REGN) are now staring down the barrel of a class action lawsuit. It seems the company’s been caught in a storm of legal action following allegations of misleading...

Aurzen Leverages Basquiat for Art-Infused Projection Line

A Fresh Perspective on Portable Projection If anyone had told me a tech brand would buddy up with the world of fine art to launch a new gadget line, I'd have raised an eyebrow. But here we are, shrugging away the standard and looking at what's cooking over at Aurzen. The company's new initiative, 'Unfold the Art,' marries the magnetism of Jean-Michel Basquiat's artwork...

Windows Storage Trends Shift: SSD Dominates 2026

SSDs Take Center Stage in Storage Evolution Howdy, storage folks! It's 2026, and one thing's for sure—SSDs are strutting their stuff at the top of the storage heap. According to the latest report by EaseUS Software, the dominant drive isn't about sheer size anymore. We've moved on to smarter space management. Now hear this: 79.73% of Windows system drives are rocking...

PinkBlush Maternity Unveils Its 2026 Fall Fashion Line

Elevating Maternity Fashion with PinkBlush's Fall 2026 Line You know, it's not every day you see maternitywear aiming to push the envelope, but that's exactly what PinkBlush is doing this fall. They've unleashed their Fall 2026 collection, and let's just say, it's less about the frills and more about redefining what expecting mothers can expect from the fashion world. A...

Ed Markey's Political Future on Shaky Ground in MA

Massachusetts Voters Voice Desire for Change Ever seen an old engine stutter and cough before finally quitting? That's what Ed Markey's political career is starting to feel like. A fresh poll has surfaced, casting doubt over his steady grip on his longstanding Senate seat in Massachusetts. People are yearning for fresh faces and new ideas like never before. It's as if the...

Reolink Unveils OMVI 2i Ultra at IFA 2026

Reolink's Bold Move Into the Future of Home Security Amidst the hustle of Berlin's IFA 2026, Reolink dropped its latest gem: the OMVI 2i Ultra—an all-in-one security powerhouse promising to change the game for home protection junkies. As usual, Reolink's got its eyes on the prize, pushing boundaries with this latest lineup. OMVI 2i Ultra: Dual-View Revolution If you've...

Baidu Joins Shanghai-HK Connect, Expanding Reach

Big News from Baidu: Connect Program Inclusion Bet you didn't see this one coming. Baidu, the titan of AI in China, just rolled out some significant buzz. Starting September 7th, their Class A ordinary shares will join the Shanghai-Hong Kong Stock Connect program, shaking things up on the Shanghai Stock Exchange. This move is set to give investors from the Chinese...

ACEMAGIC Unveils New AI Mini Workstation at IFA 2026

A Glimpse Into ACEMAGIC's Latest Innovation Look if you had told me five years ago that AI mini workstations would be making waves, I'd have probably smirked. Yet, here we are; ACEMAGIC is setting the stage at IFA 2026 in Berlin with their fresh-out-the-oven F9A AI mini workstation, powered by AMD's Ryzen AI Max+ PRO 495 processor. It all goes down from September 4 to 8...